Search Within

Urvi A Shah

  1. "Sean Devlin"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (6)
  3. Correspondence (2)
  4. Research Letter (1)
Groups
  1. Biostatistics Service (25)
  2. CTCR Scholars (25)
  3. Center for Hematologic Malignancies (25)
  4. Department of Medicine (25)
  5. Epidemiology and Biostatistics (25)
  6. Hematologic Malignancies, Division of (25)

More Groups

People
  1. Sean Devlin (25)
  2. Alexander Lesokhin (24)
  3. Sham Mailankody (24)
  4. Hani Hassoun (23)
  5. Malin Hultcrantz (23)
  6. Neha Korde (22)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (6)
  4. 2022 (3)
  5. 2021 (5)
  6. 2020 (4)

More Years

Publications
  1. Blood (10)
  2. Clinical Lymphoma, Myeloma and Leukemia (5)
  3. Blood Cancer Journal (2)
  4. Journal of Clinical Oncology (2)
  5. American Journal of Hematology (1)
  6. Biology of Blood and Marrow Transplantation (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Elsevier Inc. (6)
  3. American Society of Clinical Oncology (2)
  4. Nature Publishing Group (2)
  5. Elsevier Science, Inc. (1)
  6. John Wiley & Sons, Inc. (1)

More Publishers

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes
    Journal Article

    Valtis, Y. K.; Devlin, S.; Shouval, R.; Rejeski, K.; Corona, M.; De Abia, A. L.; Rivas-Delgado, A.; Luttwak, E.; Cassanello, G.; Landego, I.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
    Journal Article

    Costa, B. A.; Flynn, J.; Nishimura, N.; Devlin, S. M.; Farzana, T.; Rajeeve, S.; Chung, D. J.; Landau, H. J.; Lahoud, O. B.; Scordo, M.; more...
    Blood Cancer Journal (2024)

    Fulltext@MSK | Save
  • Stem cell utilization in the era of novel therapies for multiple myeloma
    Meeting Abstract

    Nishimura, N.; Nemirovsky, D.; Devlin, S. M.; Dahi, P. B.; Landau, H.; Lahoud, O. B.; Scordo, M.; Shah, G. L.; Mailankody, S.; Hassoun, H.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Successful incorporation of ePRO using PROMIS-29 into standard of care after hematopoietic stem cell transplant and chimeric antigen receptor T cell therapy for plasma cell dyscrasias
    Meeting Abstract

    Shah, G.; Lobaugh, S.; Devlin, S.; Atkinson, T.; Korde, N.; Chung, D.; Dahi, P.; Landau, H.; Lahoud, O.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Prognostic impact of corticosteroid and tocilizumab use on the efficacy of chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B.; Flynn, J.; Nath, K.; Nishimura, N.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Extreme body mass index and survival in newly diagnosed multiple myeloma patients
    Correspondence

    Shah, U. A.; Whiting, K.; Devlin, S.; Ershler, R.; Kanapuru, B.; Lee, D. J.; Tahri, S.; Gwise, T.; Rustad, E. H.; Mailankody, S.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save